Augustine Therapeutics Doses First Patient in CMT Clinical Trial of AGT-100216
Augustine Therapeutics doses the first patient in Phase I trial of AGT-100216, a potential new treatment for CMT.
Promising Results from Govorestat Trial for CMT-SORD Shared at PNS 2025
Applied Therapeutics shares promising 12-month Govorestat trial results for CMT-SORD at PNS 2025.
CMT Awareness Month 2025 – More Than You Can See
Discover the invisible side of CMT this Awareness Month and support thousands living with Charcot-Marie-Tooth disease.
Meet the New CMT Kids Leadership Team
Meet the new CMT Kids leadership team! Sam, Sophie, and Vicky are leading the way to support young people with Charcot-Marie-Tooth disease.